

Maja Mockenhaupt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5552251/publications.pdf>

Version: 2024-02-01

27
papers

2,880
citations

566801

15
h-index

454577

30
g-index

32
all docs

32
docs citations

32
times ranked

2443
citing authors

#	ARTICLE	IF	CITATIONS
1	Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. <i>Dermatology and Therapy</i> , 2022, 12, 381-393.	1.4	13
2	Epithelial Necrolysis. , 2021, , 409-422.		0
3	Drug Allergy and Cutaneous Adverse Reactions. <i>Handbook of Experimental Pharmacology</i> , 2021, 268, 195-212.	0.9	2
4	Incidence of Epidermal Necrolysis: Results of the German Registry. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2525-2527.	0.3	10
5	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41
6	EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 14-27.	2.7	149
7	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. <i>Nature Communications</i> , 2019, 10, 3569.	5.8	83
8	Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. <i>Allergo Journal International</i> , 2019, 28, 311-326.	0.9	15
9	<i>H</i> LA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2227-2230.	2.7	51
10	Making a diagnosis in severe cutaneous drug hypersensitivity reactions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 283-293.	1.1	38
11	Controversies in drug allergy: Testing for delayed reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 66-73.	1.5	144
12	Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option. <i>Frontiers in Immunology</i> , 2019, 10, 3116.	2.2	9
13	Dr. Maja Mockenhaupt. <i>Nishinohon Journal of Dermatology</i> , 2019, 81, 217-218.	0.0	0
14	Epidermal Necrolysis, Ocular Complications, and "Cold Medicines". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 703-704.	2.0	15
15	Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2017, 153, 514.	2.0	235
16	Fever in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 513-515.	1.1	29
17	New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2047-2049.	0.3	30
18	The case-crossover design via penalized regression. <i>BMC Medical Research Methodology</i> , 2016, 16, 103.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Guideline for the diagnosis of drug hypersensitivity reactions. <i>Allergo Journal International</i> , 2015, 24, 94-105.	0.9	139
20	Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review. <i>Clinical and Translational Allergy</i> , 2014, 4, P15.	1.4	1
21	The current understanding of Stevensâ€™Johnson syndrome and toxic epidermal necrolysis. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 803-815.	1.3	237
22	Stevensâ€™Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study. <i>Journal of Investigative Dermatology</i> , 2008, 128, 35-44.	0.3	807
23	Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 25-32.	0.6	393
24	Epidemiology of Staphylococcal Scalded Skin Syndrome in Germany. <i>Journal of Investigative Dermatology</i> , 2005, 124, 700-703.	0.3	80
25	Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes. <i>International Journal of Molecular Medicine</i> , 2003, 12, 597-601.	1.8	11
26	Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990â€™1992): Structure and results of a population-based registry. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 769-773.	2.4	327
27	Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2-antagonists. <i>Pharmacoepidemiology and Drug Safety</i> , 1995, 4, 207-212.	0.9	1